SIPAI HEALTH (00314) turns profit in mid-term performance: Strategic transformation shows results, and the business insurance service landscape continues to expand.

At the beginning of 2026, the "Government Work Report" proposed to "accelerate the development of commercial health insurance." Against the backdrop of the deepening collaboration between medical insurance and commercial insurance, the integration trend of commercial health insurance with health management, medical services, and other fields has further emerged, and the demand from corporate clients for comprehensive health protection services continues to grow. Recently, SIPAI HEALTH (00314) released its mid-term performance announcement for 2026. The financial report indicates that in the first half of 2026, the company achieved total revenue of approximately RMB 740 million, with an IFRS net profit of RMB 42.92 million, marking a turnaround from a net loss of RMB 81.1 million in the same period of 2025; the normalized net profit reached RMB 6.87 million, a significant improvement from a normalized net loss of RMB 12 million in 2025. The company had previously announced an earnings forecast on August 4, predicting a net profit of approximately RMB 41 million to RMB 44 million for the first half of 2026. The actual net profit disclosed in this mid-term performance report is approximately RMB 42.9 million, in line with previous expectations. Since the earnings forecast was released, the company's stock price has overall been on the rise, closing at HKD 1.53 on August 21, with a monthly increase of 13.3%. Overall, the companys performance improvement is mainly attributed to core business growth brought about by strategic transformation, optimization of business structure, and enhanced operational efficiency. Strategic transformation has yielded phased successes, further improving profitability. In the first half of 2026, SIPAI HEALTH officially turned a profit, marking a key milestone in the companys strategic transformation. The company's total revenue in the first half of the year decreased by 39.6% year-on-year to RMB 740 million, impacted by the proactive contraction of specialty pharmacy and community insurance businesses. However, as the proportion of high-margin core business increased, the overall gross profit margin rose from 14.4% in the same period of 2025 to 20.1%, an increase of 5.7 percentage points year-on-year; the IFRS net profit was RMB 42.92 million, and the normalized net profit was RMB 6.87 million, with operating profit, normalized net profit, and IFRS net profit all turning positive. At the same time, cash flow conditions also improved. The net cash outflow from operating activities in the first half of the year narrowed from RMB 63.47 million in the same period of 2025 to RMB 26.63 million, reflecting a more stable operational rhythm and a gradual improvement in the company's self-sustaining ability. While actively adjusting its revenue scale, the companys two core business segments continued to grow, further optimizing the revenue structure. Among them, corporate insurance service revenue was approximately RMB 58.93 million, a year-on-year increase of 37.7%. As of June 30, 2026, the premiums under management were approximately RMB 1.17 billion, a year-on-year increase of about 35%; the number of corporate clients reached 693, an increase of 74 from 619 at the end of 2025; about 2.13 million employees and their families benefited from services, with a medical and pharmaceutical service network covering over 300,000 service points. As the number of clients and service network continues to expand, the scale basis of this business further solidifies. The doctor research assistance business continued to maintain steady growth, with revenue in the first half of the year of about RMB 250 million, a year-on-year increase of 16.0%. SIPAI's main business in doctor research assistance is the management of clinical trial sites (SMO), a domain in which SIPAI has been deeply involved since 2014. According to the company's mid-term performance announcement, as of June 30, 2026, the company had completed a cumulative total of 1,268 SMO projects, with 925 projects in execution, and serving a clientele that includes all ten major listed pharmaceutical companies in the field of innovative drug R&D in China, with a 100% retention rate among the top ten clients. The company states that this business is not only a leader in the SMO industry but also synergizes well with its recently established life sciences insurance brokerage business. In summary, this mid-term performance report shows that while the company actively adjusts its business structure, its core businesses continue to grow, with improvements in profitability and cash flow conditions. As strategic adjustments continue to advance, the future performance of the company will depend on the further growth of core businesses, operational efficiency, and the successful implementation of new business layouts. Extending business layout around corporate insurance demands. While developing corporate health insurance business, SIPAI HEALTH is also further expanding its corporate insurance brokerage and risk management-related businesses. In the first half of 2026, the company established new departments for large enterprise risk management, reinsurance, and life sciences, and introduced relevant professionals, gradually building service capabilities covering areas such as large enterprise risk management, property insurance, liability insurance, life sciences insurance, reinsurance, and cross-border insurance. From the perspective of business layout, the company is gradually constructing a comprehensive service system that uses corporate health insurance as an entry point and extends into corporate risk management. As related business capabilities continue to improve, the company is expected to further strengthen the synergy among different insurance services, providing more comprehensive risk protection solutions for corporate clients, particularly medium and large enterprises. In conjunction with organizational restructuring, the company is also advancing the acquisition of Jianyi Information Technology. In March 2026, the company announced that it was promoting the acquisition of Jianyi, a professional insurtech and corporate health management service provider. Jianyi reportedly connects over 200 insurance institutions and nearly 300,000 medical service points, and possesses real-time claims settlement and AI data cleansing and processing capabilities. If the acquisition is completed, it is expected to enrich the corporate health management product matrix, enhance digital operations and claims settlement capabilities, and further strengthen data processing capabilities. For the specialty pharmacy segment, the company continues to promote business structure adjustments, focusing on quality improvement and efficiency enhancement, reducing operating capital occupation, and allocating more resources to core insurance businesses, professional talent acquisition, digital construction, and industrial mergers and acquisitions. In terms of the pharmaceutical service model, SIPAI's operational focus is gradually shifting from expanding pharmacy storefronts to integrating operations of high-quality networks across the country. The company disclosed that its pharmaceutical service layout has been upgraded from nearly one hundred self-operated stores to a network of "self-operated + cooperative" pharmacies covering over 300,000 nationwide. The pharmaceutical service now plays a more substantial role in supporting the infrastructure of services for corporate insurance members, achieving a service loop of insurance, health, medicine, and pharmaceuticals, balancing service accessibility with overall operational efficiency. Looking ahead, the company will continue to refine its medical health service system for corporate employees and their families around core businesses of corporate health insurance and corporate insurance brokerage, while advancing related business layouts according to market demand, gradually expanding its corporate risk management service capabilities. Overall, in the first half of 2026, SIPAI HEALTH achieved a turnaround, maintained core business growth, and improved gross margins and operating cash flow, indicating that the previous adjustments to its business structure have made phased achievements. In the future, whether the company can maintain core business growth, further improve profitability, and convert new business layouts into actual performance will remain a key focus of market attention.